NCT02448199

Brief Summary

Phase III Study, double-blind, comparing association of anti-inflammatory and anti-rheumatic in 375 subjects with knee osteoarthritis.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
375

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Jul 2015

Shorter than P25 for phase_3

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 11, 2015

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 19, 2015

Completed
1 month until next milestone

Study Start

First participant enrolled

July 1, 2015

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

May 19, 2015

Status Verified

May 1, 2015

Enrollment Period

11 months

First QC Date

May 11, 2015

Last Update Submit

May 18, 2015

Conditions

Keywords

painKnee

Outcome Measures

Primary Outcomes (1)

  • Efficacy measured by decrease in score algofunctional Lequesne index after 12 weeks from the start of treatment

    Decrease in score of algofunctional Lequesne index after 12 weeks from the start of treatment

    12 weeks

Secondary Outcomes (1)

  • Safety measured by frequency of adverse event

    12 weeks

Study Arms (3)

Kit 1 ( ML + CG ) + P

EXPERIMENTAL

One sachet meloxicam and glucosamine and 1 placebo tablet once a day for 12 weeks One sachet

Drug: Meloxicam and Glucosamine

Kit 2 ( ML + P)

ACTIVE COMPARATOR

One tablet of meloxicam and one sachet of placebo once per day for 12 weeks

Drug: Meloxicam

Kit 3 ( P+ GC)

ACTIVE COMPARATOR

One sachet of glucosamine and one tablet placebo once a day for 12 weeks

Drug: Glucosamine

Interventions

Experimental

Also known as: Association Anti-inflamatory/Anti-rheumatic
Kit 1 ( ML + CG ) + P

Active Comparator

Also known as: Anti-inflamatory/Placebo
Kit 2 ( ML + P)

Active Comparator

Also known as: Anti-rheumatic/Placebo
Kit 3 ( P+ GC)

Eligibility Criteria

Age40 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signs the Informed Consent Form
  • Age between 40 and 85 years
  • osteoarthritis of the knee according to clinical and radiological criteria of the American College of Rheumatology

You may not qualify if:

  • Cardiovascular disease
  • Serious chronic comorbidity
  • Hypersensitivity to any component of the study drugs
  • body mass index\> 30 kg / m²

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

OsteoarthritisPain

Interventions

MeloxicamGlucosamine

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

ThiazinesSulfur CompoundsOrganic ChemicalsThiazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHexosaminesAmino SugarsCarbohydrates

Study Officials

  • Edio Costa, Doctor

    CRM

    STUDY CHAIR

Central Study Contacts

Carine F Sanches, Pharmacist

CONTACT

Valery F Carvalho, Biologist

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 11, 2015

First Posted

May 19, 2015

Study Start

July 1, 2015

Primary Completion

June 1, 2016

Study Completion

July 1, 2016

Last Updated

May 19, 2015

Record last verified: 2015-05